Limits...
Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

Kulasa K, Edelman S - Core Evid (2010)

Bottom Line: Saxagliptin (Onglyza™; Bristol-Myers Squibb Company, Princeton, NJ, USA; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA) is an oral dipeptidyl peptidase-4 inhibitor, recently approved for the treatment of T2DM.Saxagliptin significantly improves glycemic control vs placebo, as demonstrated by decreasing glycated hemoglobin, fasting plasma glucose, and postprandial plasma glucose levels when used as monotherapy; in initial combination with metformin; and as add-on therapy with metformin, sulfonylurea (SU), or thiazolidinedione (TZD).Saxagliptin also significantly improves β-cell function, is weight neutral, has a low risk for hypoglycemia, and has been shown to have cardiovascular safety.

View Article: PubMed Central - PubMed

Affiliation: Division of Endocrinology and Metabolism, VA San Diego Healthcare System, University of California, USA;

ABSTRACT

Introduction: The worldwide prevalence of type 2 diabetes mellitus (T2DM) is high, and the chronically poor metabolic control that can result from T2DM is associated with a high risk for microvascular and macrovascular complications. Because of the progressive pathophysiology of T2DM, oral antidiabetic agents often fail to provide sustained glycemic control, indicating the need for new therapies. Saxagliptin (Onglyza™; Bristol-Myers Squibb Company, Princeton, NJ, USA; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA) is an oral dipeptidyl peptidase-4 inhibitor, recently approved for the treatment of T2DM.

Evidence review: Saxagliptin significantly improves glycemic control vs placebo, as demonstrated by decreasing glycated hemoglobin, fasting plasma glucose, and postprandial plasma glucose levels when used as monotherapy; in initial combination with metformin; and as add-on therapy with metformin, sulfonylurea (SU), or thiazolidinedione (TZD). Saxagliptin also significantly improves β-cell function, is weight neutral, has a low risk for hypoglycemia, and has been shown to have cardiovascular safety.

Place in therapy: The clinical profile for saxagliptin indicates that it is useful as an adjunct to diet and exercise as first-line monotherapy and in combination with metformin; or as add-on treatment for patients who cannot achieve glycemic control with a combination of diet and lifestyle changes and metformin, SU, or TZD.

No MeSH data available.


Related in: MedlinePlus

Saxagliptin 5 mg effects on HbA1c in placebo-controlled and active-controlled comparative studies.3–7,37,39,40Notes: aStatistical significance vs placebo. bStatistical significance vs comparator.Abbreviations: HbA1c, glycated hemoglobin; MET, metformin; QAM, daily before noon; QPM, daily after noon; SU, sulfonylurea; TZD, thiazolidinedione.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2963920&req=5

f3-ce-5-023: Saxagliptin 5 mg effects on HbA1c in placebo-controlled and active-controlled comparative studies.3–7,37,39,40Notes: aStatistical significance vs placebo. bStatistical significance vs comparator.Abbreviations: HbA1c, glycated hemoglobin; MET, metformin; QAM, daily before noon; QPM, daily after noon; SU, sulfonylurea; TZD, thiazolidinedione.

Mentions: Saxagliptin has been studied as monotherapy and in combination with metformin, glyburide, and the TZDs (pioglitazone and rosiglitazone) and has demonstrated glycemic efficacy regardless of age, gender, race/ethnicity, or body mass index (BMI). Although the text reports on saxagliptin effects on glycemic parameters at doses ranging from 2.5 to 100 mg, efficacy results in Table 1 and Figure 3 are presented for saxagliptin 5 mg, the usual clinical dose for patients with T2DM.3–7,37–40


Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

Kulasa K, Edelman S - Core Evid (2010)

Saxagliptin 5 mg effects on HbA1c in placebo-controlled and active-controlled comparative studies.3–7,37,39,40Notes: aStatistical significance vs placebo. bStatistical significance vs comparator.Abbreviations: HbA1c, glycated hemoglobin; MET, metformin; QAM, daily before noon; QPM, daily after noon; SU, sulfonylurea; TZD, thiazolidinedione.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2963920&req=5

f3-ce-5-023: Saxagliptin 5 mg effects on HbA1c in placebo-controlled and active-controlled comparative studies.3–7,37,39,40Notes: aStatistical significance vs placebo. bStatistical significance vs comparator.Abbreviations: HbA1c, glycated hemoglobin; MET, metformin; QAM, daily before noon; QPM, daily after noon; SU, sulfonylurea; TZD, thiazolidinedione.
Mentions: Saxagliptin has been studied as monotherapy and in combination with metformin, glyburide, and the TZDs (pioglitazone and rosiglitazone) and has demonstrated glycemic efficacy regardless of age, gender, race/ethnicity, or body mass index (BMI). Although the text reports on saxagliptin effects on glycemic parameters at doses ranging from 2.5 to 100 mg, efficacy results in Table 1 and Figure 3 are presented for saxagliptin 5 mg, the usual clinical dose for patients with T2DM.3–7,37–40

Bottom Line: Saxagliptin (Onglyza™; Bristol-Myers Squibb Company, Princeton, NJ, USA; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA) is an oral dipeptidyl peptidase-4 inhibitor, recently approved for the treatment of T2DM.Saxagliptin significantly improves glycemic control vs placebo, as demonstrated by decreasing glycated hemoglobin, fasting plasma glucose, and postprandial plasma glucose levels when used as monotherapy; in initial combination with metformin; and as add-on therapy with metformin, sulfonylurea (SU), or thiazolidinedione (TZD).Saxagliptin also significantly improves β-cell function, is weight neutral, has a low risk for hypoglycemia, and has been shown to have cardiovascular safety.

View Article: PubMed Central - PubMed

Affiliation: Division of Endocrinology and Metabolism, VA San Diego Healthcare System, University of California, USA;

ABSTRACT

Introduction: The worldwide prevalence of type 2 diabetes mellitus (T2DM) is high, and the chronically poor metabolic control that can result from T2DM is associated with a high risk for microvascular and macrovascular complications. Because of the progressive pathophysiology of T2DM, oral antidiabetic agents often fail to provide sustained glycemic control, indicating the need for new therapies. Saxagliptin (Onglyza™; Bristol-Myers Squibb Company, Princeton, NJ, USA; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA) is an oral dipeptidyl peptidase-4 inhibitor, recently approved for the treatment of T2DM.

Evidence review: Saxagliptin significantly improves glycemic control vs placebo, as demonstrated by decreasing glycated hemoglobin, fasting plasma glucose, and postprandial plasma glucose levels when used as monotherapy; in initial combination with metformin; and as add-on therapy with metformin, sulfonylurea (SU), or thiazolidinedione (TZD). Saxagliptin also significantly improves β-cell function, is weight neutral, has a low risk for hypoglycemia, and has been shown to have cardiovascular safety.

Place in therapy: The clinical profile for saxagliptin indicates that it is useful as an adjunct to diet and exercise as first-line monotherapy and in combination with metformin; or as add-on treatment for patients who cannot achieve glycemic control with a combination of diet and lifestyle changes and metformin, SU, or TZD.

No MeSH data available.


Related in: MedlinePlus